EXELIXIS, INC. — Director's Dealing 2020

Jun 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2020-06-04

Reporting Person: Schwab Gisela (Pres, Prod Dev & Med Aff & CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-04	Common Stock	M	100000	$1.70	Acquired	425963	Direct
2020-06-04	Common Stock	S	100000	$22.96	Disposed	325963	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-04	Option (right to buy)	$1.7	M	100000	Disposed	2021-09-18	Common Stock (100000.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	14880	Indirect

Footnotes

F1: Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 841 shares of common stock acquired on April 30, 2020, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019.

F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.47 to $23.46. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

F4: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of June 3, 2020.

F5: The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.